1. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice.
- Author
-
Klein C, Nguyen D, Liu CH, Mizoguchi A, Bhan AK, Miki H, Takenawa T, Rosen FS, Alt FW, Mulligan RC, and Snapper SB
- Subjects
- Animals, Colitis etiology, Colitis prevention & control, Gene Expression, Genetic Vectors, Green Fluorescent Proteins, Hematopoiesis, Hematopoietic Stem Cells metabolism, Luminescent Proteins genetics, Lymphocyte Activation, Lymphocyte Count, Mice, Mice, Knockout, Receptors, Antigen, T-Cell immunology, Retroviridae genetics, Signal Transduction, Transfection, Transplantation Chimera, Wiskott-Aldrich Syndrome complications, Wiskott-Aldrich Syndrome Protein, Colitis therapy, Genetic Therapy, Hematopoietic Stem Cell Transplantation, Proteins genetics, T-Lymphocytes immunology, Wiskott-Aldrich Syndrome therapy
- Abstract
The Wiskott-Aldrich syndrome (WAS) is an X-linked primary immunodeficiency that is caused by mutations in the recently identified WASP gene. WASP plays an important role in T-cell receptor-mediated signaling to the actin cytoskeleton. In these studies we assessed the feasibility of using retroviral gene transfer into WASP-deficient hematopoietic stem cells (HSCs) to rescue the T-cell signaling defect that is characteristic of WAS. Upon transplantation of WASP-deficient (WKO) HSCs that have been transduced with WASP-expressing retroviruses, mature B and T cells developed in normal numbers. Most importantly, the defect in antigen receptor-induced proliferation was significantly improved in T cells. Moreover, the susceptibility of colitis by WKO HSCs was prevented or ameliorated in recipient bone marrow chimeras by retrovirus-mediated expression of WASP. A partial reversal of the T-cell signaling defect could also be achieved following transplantation of WASP-deficient HSCs expressing the WASP-homologous protein N-WASP. Furthermore, we have documented a selective advantage of WT over WKO cells in lymphoid tissue using competitive repopulation experiments and Southern blot analysis. Our results provide proof of principle that the WAS-associated T-cell signaling defects can be improved upon transplantation of retrovirally transduced HSCs without overt toxicity and may encourage clinical gene therapy trials.
- Published
- 2003
- Full Text
- View/download PDF